MacroGenics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on cancer therapeutics, will participate in several investor conferences throughout November 2022. Key events include a BMO Biopharma Spotlight Series fireside chat on November 9 at 2:30 pm ET, a Stifel Healthcare Conference chat on November 15 at 10:55 am ET, and an Evercore ISI HEALTHCONx Conference chat on November 30 at 8:50 am ET. Management will also hold one-on-one meetings at these events. Webcasts will be available on the MacroGenics website.

ROCKVILLE, MD, Nov. 02, 2022 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in November 2022.

• BMO Biopharma Spotlight Series | Oncology Day (Virtual). Members of MacroGenics’ senior management team will participate in a fireside chat on Wednesday, November 9 at 2:30 pm ET. A replay link will be provided after the conference.  MacroGenics’ management will also participate in one-on-one meetings.
• Stifel 2022 Healthcare Conference (New York). MacroGenics’ President & CEO, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Tuesday, November 15 at 10:55 am ET.  MacroGenics’ management will also participate in one-on-one meetings.
  
• Evercore ISI 5^th Annual HEALTHCONx Conference (Virtual). MacroGenics’ President & CEO, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, November 30 at 8:50 am ET.  MacroGenics’ management will also participate in one-on-one meetings.
  

Webcasts of the above may be accessed under “Events & Presentations” in the Investor Relations section of MacroGenics’ website at http://ir.macrogenics.com/events.cfm.  The Company maintains archived replays of webcasts on its website for 30 days after the conference.

About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###

FAQ

What events is MacroGenics participating in during November 2022?

MacroGenics is participating in the BMO Biopharma Spotlight Series on November 9, Stifel Healthcare Conference on November 15, and Evercore ISI HEALTHCONx Conference on November 30.

When will MacroGenics hold its fireside chat at the BMO Biopharma Spotlight Series?

The fireside chat at the BMO Biopharma Spotlight Series is scheduled for November 9, 2022, at 2:30 pm ET.

Who from MacroGenics will speak at the Stifel Healthcare Conference?

Scott Koenig, M.D., Ph.D., President & CEO of MacroGenics, will participate in the fireside chat at the Stifel Healthcare Conference on November 15, 2022, at 10:55 am ET.

Where can I access webcasts of MacroGenics' conference presentations?

Webcasts can be accessed under 'Events & Presentations' in the Investor Relations section of MacroGenics' website.

What is the focus of MacroGenics as a biopharmaceutical company?

MacroGenics focuses on developing and commercializing innovative antibody-based therapeutics for cancer treatment.